210 related articles for article (PubMed ID: 19293255)
1. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Tan DS; Lambros MB; Rayter S; Natrajan R; Vatcheva R; Gao Q; Marchiò C; Geyer FC; Savage K; Parry S; Fenwick K; Tamber N; Mackay A; Dexter T; Jameson C; McCluggage WG; Williams A; Graham A; Faratian D; El-Bahrawy M; Paige AJ; Gabra H; Gore ME; Zvelebil M; Lord CJ; Kaye SB; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2009 Apr; 15(7):2269-80. PubMed ID: 19293255
[TBL] [Abstract][Full Text] [Related]
2. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets.
Hirasawa A; Saito-Ohara F; Inoue J; Aoki D; Susumu N; Yokoyama T; Nozawa S; Inazawa J; Imoto I
Clin Cancer Res; 2003 Jun; 9(6):1995-2004. PubMed ID: 12796361
[TBL] [Abstract][Full Text] [Related]
3. Tiling path genomic profiling of grade 3 invasive ductal breast cancers.
Natrajan R; Lambros MB; Rodríguez-Pinilla SM; Moreno-Bueno G; Tan DS; Marchió C; Vatcheva R; Rayter S; Mahler-Araujo B; Fulford LG; Hungermann D; Mackay A; Grigoriadis A; Fenwick K; Tamber N; Hardisson D; Tutt A; Palacios J; Lord CJ; Buerger H; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2009 Apr; 15(8):2711-22. PubMed ID: 19318498
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
Hirata Y; Murai N; Yanaihara N; Saito M; Saito M; Urashima M; Murakami Y; Matsufuji S; Okamoto A
BMC Cancer; 2014 Nov; 14():799. PubMed ID: 25366985
[TBL] [Abstract][Full Text] [Related]
5. PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study.
Lambros MB; Natrajan R; Geyer FC; Lopez-Garcia MA; Dedes KJ; Savage K; Lacroix-Triki M; Jones RL; Lord CJ; Linardopoulos S; Ashworth A; Reis-Filho JS
Mod Pathol; 2010 Oct; 23(10):1334-45. PubMed ID: 20543821
[TBL] [Abstract][Full Text] [Related]
6. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours.
Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A
Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685
[TBL] [Abstract][Full Text] [Related]
7. PPM1D is a potential target for 17q gain in neuroblastoma.
Saito-Ohara F; Imoto I; Inoue J; Hosoi H; Nakagawara A; Sugimoto T; Inazawa J
Cancer Res; 2003 Apr; 63(8):1876-83. PubMed ID: 12702577
[TBL] [Abstract][Full Text] [Related]
8. A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D.
Rayter S; Elliott R; Travers J; Rowlands MG; Richardson TB; Boxall K; Jones K; Linardopoulos S; Workman P; Aherne W; Lord CJ; Ashworth A
Oncogene; 2008 Feb; 27(8):1036-44. PubMed ID: 17700519
[TBL] [Abstract][Full Text] [Related]
9. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
[TBL] [Abstract][Full Text] [Related]
10. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function.
Proia DA; Nannenga BW; Donehower LA; Weigel NL
J Biol Chem; 2006 Mar; 281(11):7089-101. PubMed ID: 16352595
[TBL] [Abstract][Full Text] [Related]
11. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas.
Brown LA; Irving J; Parker R; Kim H; Press JZ; Longacre TA; Chia S; Magliocco A; Makretsov N; Gilks B; Pollack J; Huntsman D
Gynecol Oncol; 2006 Feb; 100(2):264-70. PubMed ID: 16236351
[TBL] [Abstract][Full Text] [Related]
12. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.
Mendrzyk F; Radlwimmer B; Joos S; Kokocinski F; Benner A; Stange DE; Neben K; Fiegler H; Carter NP; Reifenberger G; Korshunov A; Lichter P
J Clin Oncol; 2005 Dec; 23(34):8853-62. PubMed ID: 16314645
[TBL] [Abstract][Full Text] [Related]
13. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient.
Yamamoto S; Tsuda H; Miyai K; Takano M; Tamai S; Matsubara O
Mod Pathol; 2011 Aug; 24(8):1146-55. PubMed ID: 21478826
[TBL] [Abstract][Full Text] [Related]
14. PP2Cdelta (Ppm1d, WIP1), an endogenous inhibitor of p38 MAPK, is regulated along with Trp53 and Cdkn2a following p38 MAPK inhibition during mouse preimplantation development.
Hickson JA; Fong B; Watson PH; Watson AJ
Mol Reprod Dev; 2007 Jul; 74(7):821-34. PubMed ID: 17219434
[TBL] [Abstract][Full Text] [Related]
15. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
16. Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma.
Schraml P; Schwerdtfeger G; Burkhalter F; Raggi A; Schmidt D; Ruffalo T; King W; Wilber K; Mihatsch MJ; Moch H
Am J Pathol; 2003 Sep; 163(3):985-92. PubMed ID: 12937139
[TBL] [Abstract][Full Text] [Related]
17. Identification of differentially expressed genes after PPM1D silencing in breast cancer.
Pärssinen J; Alarmo EL; Khan S; Karhu R; Vihinen M; Kallioniemi A
Cancer Lett; 2008 Jan; 259(1):61-70. PubMed ID: 17977650
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.
Rahman MT; Nakayama K; Rahman M; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Cancer; 2012 Jun; 118(11):2846-57. PubMed ID: 22139760
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23.
Li J; Yang Y; Peng Y; Austin RJ; van Eyndhoven WG; Nguyen KC; Gabriele T; McCurrach ME; Marks JR; Hoey T; Lowe SW; Powers S
Nat Genet; 2002 Jun; 31(2):133-4. PubMed ID: 12021784
[TBL] [Abstract][Full Text] [Related]
20. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
Pärssinen J; Alarmo EL; Karhu R; Kallioniemi A
Cancer Genet Cytogenet; 2008 Apr; 182(1):33-9. PubMed ID: 18328948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]